A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
| Status: | Completed |
|---|---|
| Conditions: | Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/10/2018 |
| Start Date: | March 15, 2016 |
| End Date: | May 26, 2017 |
A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection
The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with
Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients
with liver cirrhosis.
Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients
with liver cirrhosis.
For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation,
please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Genotype 3 HCV
- HCV RNA ≥10000 IU (International Unit)/mL
- Compensated Liver Cirrhosis
- BMI 18-40 kg/m2
- Previously treated for HCV or never treated for HCV
Exclusion Criteria:
- Infection with HCV other than Genotype 3. Mixed infection of any genotype
- Evidence of decompensated liver disease
- Previous exposure to NS5A inhibitors
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
13
sites
Click here to add this to my saved trials
Inova Fairfax Hospital Inova Fairfax Hospital, Inova's flagship hospital, is an 833-bed, nationally recognized regional...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials